MUROMACHI CHEMICALS INC. Logo

MUROMACHI CHEMICALS INC.

A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.

4885 | T

Overview

Corporate Details

ISIN(s):
JP3914800002
LEI:
Country:
Japan
Address:
大牟田市新勝立町一丁目38番5
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Muromachi Chemicals Inc. is a diversified manufacturer operating across four core business segments. The Pharmaceutical division produces and sells medical products and active pharmaceutical ingredients (APIs). The Chemical business specializes in high-performance, customized liquid treatment systems for various applications, including environmental solutions. The Consumer Healthcare division manufactures and markets health foods. Additionally, the Functional Materials segment supports customer development with a broad range of standard and custom-made products for diverse markets. Founded in 1917, the company leverages its long-standing expertise to develop and provide innovative solutions that contribute to health and society.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-26 03:41
Registration Form
確認書
Japanese 8.7 KB
2025-08-26 03:40
Registration Form
有価証券報告書-第79期(2024/06/01-2025/05/31)
Japanese 1020.4 KB
2025-01-14 08:01
Report Publication Announcement
確認書
Japanese 8.7 KB
2025-01-14 08:00
Interim Report
半期報告書-第79期(2024/06/01-2025/05/31)
Japanese 214.1 KB
2024-09-04 03:00
Post-Annual General Meeting Information
臨時報告書
Japanese 27.6 KB
2024-08-28 08:34
Governance Information
内部統制報告書-第78期(2023/06/01-2024/05/31)
Japanese 22.8 KB
2024-08-28 08:32
Registration Form
有価証券報告書-第78期(2023/06/01-2024/05/31)
Japanese 986.7 KB
2024-08-28 08:32
Registration Form
確認書
Japanese 8.7 KB
2024-04-12 09:01
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-04-12 09:01
Quarterly Report
四半期報告書-第78期第3四半期(2023/12/01-2024/02/29)
Japanese 178.7 KB
2024-01-12 08:02
Quarterly Report
四半期報告書-第78期第2四半期(2023/09/01-2023/11/30)
Japanese 213.9 KB
2024-01-12 08:02
Report Publication Announcement
確認書
Japanese 8.7 KB
2023-10-13 09:02
Registration Form
確認書
Japanese 8.7 KB
2023-10-13 09:01
Quarterly Report
四半期報告書-第78期第1四半期(2023/06/01-2023/08/31)
Japanese 182.3 KB
2023-08-29 03:35
Post-Annual General Meeting Information
臨時報告書
Japanese 24.0 KB

Automate Your Workflow. Get a real-time feed of all MUROMACHI CHEMICALS INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MUROMACHI CHEMICALS INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MUROMACHI CHEMICALS INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America
NEO
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
NEONC TECHNOLOGIES HOLDINGS, INC. Logo
Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.
United States of America
NTHI
Neumora Therapeutics, Inc. Logo
Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.
United States of America
NMRA
Neuphoria Therapeutics Inc. Logo
Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.
United States of America
NEUP
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America
NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America
NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden
NEWBRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.